Periscope Capital’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-196,896
Closed -$57.6K – 908
2022
Q4
$57.6K Buy
196,896
+37,096
+23% +$7.47K ﹤0.01% 550
2022
Q3
$11K Buy
159,800
+5,000
+3% +$546 ﹤0.01% 993
2022
Q2
$15K Hold
154,800
– – ﹤0.01% 1035
2022
Q1
$31K Hold
154,800
– – ﹤0.01% 1052
2021
Q4
$88K Buy
+154,800
New +$98.9K ﹤0.01% 856

Periscope Capital's EBACW Position: Q1 2023 in Review

Periscope Capital sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 196,896 shares — an estimated $57.6K sold.

Periscope Capital first reported a position in EBACW in Q4 2021 and held it in 5 quarters. The position peaked at $88K in Q4 2021. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

  • Periscope Capital reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
  • Periscope Capital sold 196,896 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $57.6K.
  • Periscope Capital first reported a position in European Biotech Acquisition Corp. Warrant in Q4 2021 and held it in 5 quarters.
  • Periscope Capital's European Biotech Acquisition Corp. Warrant position peaked at $88K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on Periscope Capital's 13F filing for Q1 2023, filed 12 May 2023.